Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Birgit Wilding(Boehringer Ingelheim (Germany)), Ralph A. Neumüller(Boehringer Ingelheim (Austria))
Cited by 43
Related Papers
Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer
|Genes & Development|2009|404